BioXcel Therapeutics Announces First Patient Dosed in TRANQUILITY III Phase 3 Trial for Acute Treatment of Agitation in Patients with Alzheimer’s Disease
Pivotal trial will evaluate efficacy and safety of BXCL501 in Alzheimer’s patients in nursing homes…
Four Inc. Secures Spot on Washington Technology’s Top 100 Government Contractors List for 11th Consecutive Year
Tat Hong Equipment Service Co., Ltd. Announces 2025/26 Annual Results